Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72984 | 0.89 | SIRT1 (0.48) | CYP19A1SIRT1MAOBHSD17B10ADORA3 | |
| SCHEMBL27893072 | 0.89 | SIRT1 (0.48) | CYP19A1SIRT1MAOBHSD17B10ADORA3 | |
| Charcoal, Activated SCHEMBL2025121 | 0.88 | SIRT1 (0.47) | CYP19A1SIRT1MAOBHSD17B10ADORA3 | |
| Flavanone SCHEMBL14126568 | 0.81 | MAOB (0.69) | CYP19A1MAOBHSD17B10ADORA3KDM4E | |
| SCHEMBL21248251 | 0.81 | MAOB (0.47) | CYP19A1SIRT1MAOBCTRCESR1 | |
| Pyrrole SCHEMBL28505040 | 0.81 | SIRT1 (0.42) | CYP19A1SIRT1MAOBHSD17B10ADORA3 | |
| SCHEMBL17985004 | 0.78 | CYP19A1 (0.49) | CYP19A1SIRT1MAOBALDH1A1ALDH2 | |
| SCHEMBL2854127 | 0.78 | CYP19A1 (0.49) | CYP19A1SIRT1MAOBMAOAESR1 | |
| SCHEMBL4806205 | 0.78 | MAPT (0.46) | SIRT1HSD17B10ADORA3KDM4EESR1 | |
| SCHEMBL31547349 | 0.78 | MAPT (0.46) | SIRT1HSD17B10ADORA3KDM4EESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931345-B1 | SULFASALAZINE FOR TREATING SARCOIDOSIS, THIOL-CONTAINING COMPOUND DEFICIENT CONDITION | NAT JEWISH HEALTH (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2011-11-24 | — | — | US | disclosed |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | DAY BRIAN J | 2011-05-05 | — | — | US | disclosed |
| US-7790762-B2 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH HEALTH (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2217259-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Health (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1562563-B1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH HEALTH (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009052411-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7498047-B2 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1931345-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007073518-A9 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | NAT JEWISH MED & RES CENTER (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007073518-A2 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007024741-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1562563-A4 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH MED & RES CENTER (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1562563-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004042020-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | ABCC1, ABCC2, ABCB1 | CYP19A1 4330/4885SIRT1 2237/4885MAOB 3654/4885 |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | ABCC1, CFTR, ABCC2 | CYP19A1 4630/4885SIRT1 1681/4885MAOB 3660/4885 |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | CYP19A1 3558/4885SIRT1 3337/4885MAOB 3514/4885 |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | ABCC2, CFTR, ABCC1 | CYP19A1 4717/4885SIRT1 2850/4885MAOB 2867/4885 |
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | CYP19A1 3558/4885SIRT1 3337/4885MAOB 3514/4885 |
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | ABCC1, CFTR, SLC47A1 | CYP19A1 4468/4885SIRT1 2406/4885MAOB 2367/4885 |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | ABCC1, ABCC2, ABCB1 | CYP19A1 4330/4885SIRT1 2237/4885MAOB 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.